摘要
目的:初步考察成人危重症患者应用亚胺培南/西司他丁发生中枢神经系统不良反应的发生率及其危险因素。方法:采用回顾性研究的方法,收集2017年1月1日–12月31日我院使用亚胺培南/西司他丁的成人危重症患者信息,并应用Naranjo评分量表评价亚胺培南/西司他丁与中枢神经系统不良反应的相关性。使用SPSS 22.0软件对患者的人口学资料、既往病史、现病史、合并用药等情况进行统计分析,考察影响不良反应发生的因素。结果:73例危重症患者中,13例(17.81%)患者的中枢神经系统症状可能与亚胺培南/西司他丁相关。统计结果显示,接受肾替代治疗(P=0.032)是导致中枢神经系统不良反应的危险因素。结论:对于接受肾替代治疗的危重症患者在应用亚胺培南/西司他丁时,应严密监护中枢神经系统不良反应。
Objective: To investigate the occurrence and risk factors of adverse drug reactions (ADRs) of central nervous system (CNS) induced by imipenem/cilastatin in adult critically ill patients. Methods: A retrospective study was performed in adult critically ill patients treated with imipenem/cilastatin from January to December in 2017. The Naranjo scale was used to evaluate the relativity between imipenem/cilastatin and ADRs of CNS. Patients' characteristics including demographic information, past and current medical history, combined medication were analyzed by SPSS 22.0 to explore the possible risk factors of imipenem/ cilastatin-related CNS ADRs. Results: A total of 73 cases were enrolled in this study. 13 cases (17.81%) were identified to have CNS symptoms associated with imipenem/cilastatin. Renal replacement therapy (P = 0.032) was a risk factor of imipenem/cilastatinrelated CNS ADRs. Conclusion: Critically ill patients, especially those with renal replacement therapy, should be closely monitored to advoid CNS ADRs during imipenem/cilastatin therapy.
作者
温爱萍
李丹丹
鲍晓龙
WEN Ai-ping;LI Dan-dan;BAO Xiao-long(Department of Pharmacy, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, China;Department of Pharmacy, Beijing Fengtai You'anmen Hospital, Beijing 100069, China)
出处
《中国药物应用与监测》
CAS
2019年第2期89-92,共4页
Chinese Journal of Drug Application and Monitoring
基金
北京药学会临床药学研究项目
